Company

Corporate History Corporate History

  • 2021
  • 2011~2020
  • 2000~2010
  • 1992~1999
History 2011~2015
History 2021
2021~ 2011~2015
  • 2021
  • Received 2021 The Most Trusted Brand Award in arthritis treatment
    Samyang Biopharm incorporated Medichem
    Samyang Holdings incorporated Samyang Biopharmaceuticals
History 1992~1999
2011~2015 2011~2015
  • 2020
  • Acquired the product license for Everose Tab.
    Established Samyang Biopharm Hungary and carried out an investment announcement
    Launched Neosorb®Plus
  • 2019
  • Renewed EU GMP certificate
    Biodegradable surgical suture designated as World Class Product of Korea
    License agreement for immuno-oncology new drug candidate substance
    License agreement for metabolic-oncology new drug candidate substance
  • 2018
  • Established Samyang Biopharm USA. Inc. (Cambridge)
    Launched Lenalid® Tab, Decilid, Azalid (drugs for Hematology)
    Ranked No. 1 in domestic sales of Paclitaxel Injections
    Acquired the product license for MONOFIX™, which is a Knotless Wound Closure Device
    Received 50 million export award(“Export Top Award”) by Korea International Trade Association
  • 2017
  • Acquired the product license for Q-Guard®, which is a Hemostatic Dressing (Non-Absorbable)
    Acquired Medichem to ensure a stable supply of biodegradable suture raw materials
    04Global Symposium commemorating the completion of the Samyang Discovery Center
    03Completed the expansion of the pharmaceuticals plant (Anti-cancer drugs)
  • 2016
  • 07Completed the Samyang Discovery Center
    06 Designated by the Ministry of Industry as an Advanced technology center (ATC)
  • 2015
  • 09Acquired the product license for Protezomib® Inj, which is an anticancer drug
    07Acquired the product license for Pemed® S liquid Inj, which is an anticancer drug
    05Acquired the product license for SurgiGuard® , which is a hemostatic agent(Fabric, Fibrillar and Non-Woven type)
  • 2014
  • 12Acquired the product license for InterGuard® , which is an adhesion barrier
    09Acquired the product license for SurgiGuard®, which is a hemostatic agent(Original type)
  • 2013
  • 07 Merged with Samyang Genexbio Corp.
    06Acquired the product license for Neosorb® Plus, a suture that contains medication
    05Launched Nanoxel® M, which is an anticancer drug, and Pentaderm®, which is an analgesic.
  • 2012
  • 10Samyang Biopharmaceuticals Corp. designated as a technical research personnel enterprise
    07Achieved sales of 100,000 km per year for surgical suture (total amount of bulk)
    06Certified as an Innovative pharmaceutical company by the Ministry of Health and Welfare
  • 2011
  • Established the Samyang Holding Corp. and Samyang Biopharmaceuticals Corp.
History 1992~1999
2000~2010 2000~2010
  • 2010
  • 06Launched the Neosorb® Plus (antibacterial absorbable suture)
    01Genexol® PM added an indication for ‘the use of breast cancer second-line treatment’
  • 2009
  • 11Docetaxel-PNP selected for the healthcare business project
    10Docetaxel-PNP received IND approval
    09Launched Monolene (Polypropylene suture)
    08Genexol® PM obtained the product license in India and received IND approval on stage 2 ovarian cancer
    06Genexol® PM obtained the product license in Vietnam / Philippines
  • 2008
  • 11Docetaxel-PM received IND approval
  • 2007
  • 02Received the Excellence Award from the 8th Korea New Drug Development Award
    02Launched the Genexol® PM
    02Acquired the product license for Proflex® Mesh, which is a partially absorbable surgical mesh
  • 2006
  • 12Completed the expansion of the MD plant
    12Genexol® PM received the ‘Ministry of Health and Welfare Minister's Award’ and was selected as an ‘Excellent Research Institute for Promoting the Application of Research Performance’
    12Genexol® PM selected as the supporting business for overseas technology transfer
    09Launched the Neosorb® suture
    09Genexol® PM authorized to market for lung/breast cancer
  • 2005
  • 12Launched the Nicostop® Troche
    03Signed business agreement with Akina, Inc. (U.S) on Cetirizine FDT
    03Launched the Monofast® suture
  • 2004
  • 06Clinical trial for Genexol® PM on stage 2 breast cancer at Asan Medical Center, etc.
  • 2003
  • 12Clinical trial for Genexol® PM on stage 2 lung cancer at Seoul National University Hospital, etc.
    08Clinical trial for Genexol® PM on stage 2 breast cancer at Seoul National University Hospital, etc.
  • 2002
  • 06Established SRC, a pharmaceutical research cooperation (Utah, U.S.)
    05Genexol® PM received IND approval in the U.S
  • 2001
  • 10Acquired the license for Genexol® PM inj [100mg]
    06Acquired the license for Genexol® PM inj [30mg]
  • 2000
  • 08Granted the CE mark for Surgisorb® and Biomesh®
History 1992~1999
1992~1999 1992~1999
  • 1999
  • 12Medical devices certified for ISO 9001 & EN 46001
    08Medical device certified for KGMP
    08Launched the Monosorb® suture
  • 1998
  • 12Acquired the license and launched the Genexol® injection (June 1st, 2001)
  • 1997
  • 12Completed the pharmaceutical plant
    08Trisorb® received the Jang Young Shil Award
  • 1996
  • 11Pharmaceuticals certified for KGMP
    07Completed the MD plant
    03Launched the Trisorb® suture
  • 1994
  • 10Medical suture awarded the patented technology prize
  • 1993
  • 10Acquired the KT (Korean technology) mark for the medical suture
  • 1992
  • 09Established the Biopharmaceuticals R&D Center

inquiry